Clinical Trials
19 trialsNCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT06553339 2024-08-14
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT02110563 2024-07-11
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Novo Nordisk A/S
Phase 1 Terminated
NCT02549937 2024-07-10
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT02736565 2023-11-13
Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Gradalis, Inc.
Phase 1 Completed
NCT01222767 2021-10-29
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
PharmaMar
Phase 2 Completed
NCT02955069 2021-04-12
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Novartis
Phase 2 Completed
NCT02355535 2020-09-24
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Vanquish Oncology, Inc.
Phase 1 Completed
NCT00668148 2018-07-17
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Eli Lilly and Company
Phase 2 Completed
NCT02132468 2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2 Completed
NCT01374451 2016-12-20
COOPERATE-2
Novartis
Phase 2 Terminated
NCT00563680 2016-10-27
QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
NantCell, Inc.
Phase 2 Completed
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT01658436 2016-05-02
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Novartis
Phase 2 Completed
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated
NCT01381822 2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1 Unknown
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00006368 2013-05-01
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Phase 1 Completed